Generics & Biosimilars | Association for Accessible Medicines
New Blog - Inflation Rebate Proposal Builds on Bad Policy for Generics
Learn More
Close
  • Doesn't Add Up patient photo
    Congress Needs To Hear From You!
    Lawmakers are actively considering prescription drug reforms included in the Build Back Better Act (H.R. 5376) that would undermine patient access to affordable FDA-approved generic and biosimilar medicines. Tell your Senator not to put these medicines at risk!
    Take Action!
  • AAM 2021 U.S. Generic and Biosimilar Medicines Savings Report. October 2021.
    AAM Encourages Congress to Protect Patient Savings
    Competition from lower-cost generics and biosimilars has successfully led to decades of savings for patients. AAM strongly opposes negotiations in Medicare that would jeopardize these savings.
    Learn More
  • AAM All Access Podcast
    Featured AAM All Access Podcast: Bob Pollock
    Lachman Consultants Senior Advisor Robert (Bob) Pollock shares his experiences at FDA in the early days of the generics industry, the backbone of today's pharmaceutical business.
    Listen to Podcast
  • Access! 2022 – AAM Annual Meeting 2022
    Access! 2022
    Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Plan to join us in person for the first time since 2019 in Orlando!  Early bird $500 savings off full-pass registration available until December 31, 2021.
    Register Today
  • GRx+Biosims 2021: Generics & Biosimilars Conference — Progress + Process
    GRx+Biosims 2021
    Thank you to our incredible lineup of speakers and to everyone who attended GRx+Biosims 2021! We hope to see you again next year. Check out Twitter for conference highlights with #GRxBiosims.
    Follow #GRxBiosims on Twitter
  • AAM 2021 U.S. Generic and Biosimilar Medicines Savings Report. October 2021.
    2021 U.S. Generic and Biosimilar Medicines Savings Report
    Report reveals continued savings growth through lower-cost generic and biosimilar competition. The findings reinforce the outsized importance of the industry delivering lifesaving & health-managing medicines.
    View Full Report
  • AAM Patient Report: Voices of Access
    Patient Stories: Voices of Access
    AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.
    Meet the AAM Patients

Working to leave a positive impact on...

Industry Industry We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More
People People We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More
Policy Policy We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Who We Are

Recent Updates

Our Brands and Campaigns

Association for Accessible Medicines

601 New Jersey Ave NW, Suite 850
Washington DC 20001

 

202.249.7100
info@accessiblemeds.org

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.